Is JNJ Stock Setup For A Rerating?
Johnson & Johnson (JNJ) stock trades at $222.51 per share, a market cap of $536.0B, and 25.5 times trailing earnings. Is that a fair price, or is there more going on here?
Where JNJ Sits Today
- Valuation: P/E of 25.5 versus a 3-year average of 20.6 and a 3-year high of 32.9.
- Revenue: Revenue grew 7.9% over the last 12 months, with a 3-year CAGR of 4.4%.
- Net Margin: Running at 21.8% LTM, against a 3-year average of 27.1% and a 3-year peak of 44.9%.
While the table below shows the same picture in one place, you can internalize JNJ’s current state better with a more detailed financial picture.
| JNJ | |
|---|---|
| Sector | Health Care |
| Industry | Pharmaceuticals |
| P/E Ratio | 25.5 |
| P/E Ratio 3Y Avg | 20.6 |
| LTM* Revenue Growth | 7.9% |
| 3Y Avg Revenue Growth | 4.4% |
| LTM* Net Margin | 21.8% |
| 3Y Peak Net Margin | 44.9% |
| 3Y Avg Net Margin | 27.1% |
*LTM: Last Twelve Months
- Johnson & Johnson Stock On A Winning Streak: Time To Get In Or Book Profits?
- Stronger Bet Than Johnson & Johnson Stock: JAZZ Delivers More
- JNJ Stock’s 60% Breakout: Why Wall Street is Torn
- Should You Pay Attention To Johnson & Johnson Stock’s Momentum?
- Johnson & Johnson Stock Surged 60%, Here’s Why
- Does Johnson & Johnson Stock Have More Upside?
Revenue Compounding Does The Work
JNJ has shown a clear acceleration from a low base, stepping up to 7.9% LTM. We allow this recovery momentum to hold, projecting 9.8% annually.
Even with these conservative guardrails, compounding moves the earnings base enough to deliver the upside here. Margins and multiples are not asked to stretch.
The 3-Year Math
A straightforward scenario, not a forecast. Here is what the numbers look like.
- Revenue grows at 9.8% annually (sustaining the recent recovery momentum from a low base), and reaches $127.7B from $96.4B today.
- Net Margin drifts from 21.8% toward the 3-year average of 27.1%, landing at 23.4%.
- Earnings combine the two. The base moves to roughly $29.9B from $21.0B today, about a 42% jump.
- P/E eases from 25.5 to 22.9, a partial reversion from above-average levels back toward the 3-year average of 20.6.
Apply the projected multiple to the projected earnings base: stock price lands near $284.75, a market cap of $685.9B against $536.0B today. That is roughly 28% above where the stock trades now.
Revenue compounding might be the key to JNJ’s upside going forward. But did the same lever drive its recent move or was it something different?
What Has To Be True
Revenue needs to keep compounding near 9.8% annually. Sustained deceleration below this level shrinks the earnings base and aggressively pressures the multiple.
One thing to watch: JNJ’s multiple is currently above its 3-year average. The scenario builds in partial mean-reversion, but if the P/E compresses more violently than assumed, some upside evaporates.
Worth flagging: JNJ share count is down about 7.6% over the last 3 years. That buyback pace means even flat net income translates to rising EPS, compounding with whatever the main scenario delivers.
The 3-year horizon is a convenience. Whether this plays out over 3 years or 5, the stock price is likely to respond in a similar direction, as long as the trajectory holds.
When One Stock Isn’t The Whole Answer
A careful 3-year case on a single name is still a concentrated bet, as analysis of its volatility during past market crises shows. Investors who build analyses like this on individual positions often want the same framework running across a diversified book – partly for discipline, partly because even the cleanest single-stock thesis can break for reasons the math does not capture.
The Trefis High Quality (HQ) Portfolio combines the analytical rigor with forward looking view across 30 stocks, with a consistent selection framework and a sizing and rebalancing discipline designed to deliver upside without the single-name risk you just read through here.
By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000.